Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Hymecromone by Halo Biosciences for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease): Likelihood of Approval
Hymecromone is under clinical development by Halo Biosciences and currently in Phase II for Interstitial Lung Diseases (Diffuse Parenchymal Lung...